Back to Research

Organization profile

Quant Biomarkers

Quant Biomarkers is a precision medicine and diagnostics company that develops AI-driven platforms and novel biomarker panels for the early detection and management of cardio-renal and metabolic diseases. The organization focuses on identifying structural alterations in proteins to predict disease progression and optimize therapeutic interventions in aging populations.

Basel, SwitzerlandFounded 2022

Overview

1. Executive Summary (Confidence: High)

Quant Biomarkers is at the forefront of the "longevity diagnostics" movement, bridging the gap between advanced analytical chemistry and digital health. Headquartered in Basel and founded in 2021, the company targets Chronic Kidney Disease (CKD) and metabolic syndrome through two flagship products: RenoRisk Detect and RenoPredict.[23] By utilizing top-down mass spectrometry to identify specific isoforms of Human Serum Albumin (HSA), the company achieves higher sensitivity than conventional tests, enabling the detection of organ damage long before clinical symptoms appear.[24] Their strategic value lies in a multi-stakeholder business model that serves clinicians, pharmaceutical R&D, and the insurance industry, offering a clear ROI through early intervention and the reduction of healthcare costs associated with aging.[26]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.